BioSpace News Archive

Minimally invasive image-guided therapy start-up, SpinaFX Medical Inc. (SpinaFX) is pleased to announce the signing of a commercialization contract manufacturing agreement with StarFish Product Engineering Inc. (“StarFish Medical”), Canada’s largest medical device design, development, and manufacturing services organization.

Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced that the company’s universal cancer vaccine, UV1, will be investigated in a new Phase II clinical trial in combination with pembrolizumab in non-small cell lung cancer (NSCLC).

RaySearch Laboratories AB (publ) and IBA announce that they expand their partnership in proton therapy within the areas of FLASH radiotherapy, proton ARC therapy, and treatment of moving tumors.

Jaguar Gene Therapy, a company accelerating breakthroughs in gene therapy for larger patient populations suffering from severe genetic diseases, announced plans for a commercial manufacturing facility in Durham, North Carolina.

Evotec SE announced that it has commenced a public offering in the United States of up to 22,000,000 American Depositary Shares representing 11,000,000 of its ordinary shares pursuant to a registration statement on Form F-1, as amended, filed with the U.S. Securities and Exchange Commission.

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today it will release its third quarter financial results on Tuesday, November 9, 2021.

Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced the Phase 3 trial of Angion’s ANG-3777 did not demonstrate a statistically significant difference from placebo on the primary endpoint (eGFR at 12 months) in the population of deceased donor kidney transplant patients who were at risk for developing delayed graft function (DGF).

Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring systems for people with diabetes, announced that it plans to release its third quarter 2021 financial results after market close on Tuesday, November 9, 2021.

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced that Julie Eastland has been named President and Chief Executive Officer, effective November 8, 2021.

Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 48,800 shares of the Company’s common stock at an exercise price per share of $34.38, which was the closing price on October 25, 2021.